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Abstract 
Objective. Ten years ago, the METEOR tool was developed to simulate treatment-to-target and 
create an international research database. The development of the METEOR tool and database, 
research opportunities and future perspectives are described. 
Methods. The METEOR tool is a free, online, internationally available tool in which daily practice 
visits of all rheumatoid arthritis patients visiting a rheumatologist can be registered. In the tool, 
disease characteristics, patient and physician reported outcomes and prescribed treatment could be 
entered. These can be subsequently displayed in powerful graphics, facilitating treatment decisions 
and patient-physician interactions. An upload facility is also available, by which data from local 
electronic health record systems or registries can be integrated into the METEOR database. This is 
currently being actively used in, among other countries, the Netherlands, Portugal and India. 
Results. Since an increasing number of hospitals use electronic health record systems, the upload 
facility is being actively used by an increasing number of sites, enabling them to benefit from the 
benchmark and research opportunities of METEOR. Enabling a connection between local registries 
and METEOR is a well established but time-consuming process for which an IT-specialist of METEOR 
and the local registry are necessary. However, once this process has been finished, data can be 
uploaded regularly and relatively easily according to a pre-specified format. The METEOR database 
currently contains data from >39,000 patients and >200,000 visits, from 32 different countries and is 
ever increasing. Continuous efforts are being undertaken to increase the quality of data in the 
database. 
Conclusion. Since METEOR has been founded 10 years ago, many rheumatologists worldwide have 
used the METEOR tool to follow-up their patients and improve the quality of care they provide to 
their patients. Combined with uploaded data, this has led to an extensive growth of the database. It 
now offers a unique opportunity to study daily practice care and to perform research regarding 
cross-country differences in a large, worldwide setting, which could provide important knowledge 
about disease and its treatment in different geographic and clinical settings.  
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Introduction 
Treat-to-target has been repeatedly shown to be highly effective in rapidly reducing disease activity 
in rheumatoid arthritis (RA) patients [1]. Such treat-to-target strategy requires a long-term follow-up 
of patients with regular assessments of treatment effectiveness, using validated disease activity 
measures such as the Disease Activity Score[2] (DAS), the Simplified Disease Activity Index[3] (SDAI) 
or the Composite Disease Activity Index[4] (CDAI). Although highly effective, treat-to-target is not 
always followed in clinical practice[5], possibly because it is not always easy to obtain a fast disease 
activity measurement. Therefore 10 years ago, in 2006, the Measurement of Efficacy of Treatment in 
the “Era of Outcome” in Rheumatology (METEOR) tool was developed to stimulate treat-to-target, 
improve patient care and create an international RA research database[6].  
The METEOR tool 
The METEOR tool is a free, online tool available worldwide in different languages. The tool is entirely 
web-based and easy to use and can therefore be used without involvement of the local IT 
department. Within each centre using METEOR, one coordinator (e.g. a rheumatologist or research 
nurse) is appointed and receives administrator rights from the METEOR organisation. This 
administrator can create all user accounts necessary for that centre. All METEOR users within each 
centre can access the METEOR tool with their own account and can at the same time access all 
patient data entered by their colleague users in the same centre. This easy implementation strategy 
has facilitated worldwide spread of the METEOR tool. 
In the tool, data of all RA patients visiting a rheumatologist can be entered. This can be new as well 
as existing RA patients, who are followed according to usual care. Each visit of the patient can be 
registered in METEOR. In 7 structured screens within the tool, data about patient and disease 
characteristics, patient and physician reported outcomes and prescribed treatment could be 
registered (table 1). Based on the available data, the tool automatically calculates a range of disease 
activity scores: DAS, DAS-3 (DAS calculated with 3 components), DAS28 (DAS based on 28 joint 
count), DAS28-3 (DAS based on 28 joint count and 3 components), SDAI, CDAI and Routine 
Assessment of Patient Index Data (RAPID3) [7]. Medications, disease activity and physical functioning 
are subsequently displayed in illustrative and user-friendly graphics, facilitating treatment decisions 
and patient-physician interactions. The METEOR tool also offers benchmarking possibilities, to 
compare patient data, care indicators and treatment at the level of the rheumatologist, site, country 
or the complete METEOR database. Furthermore, it is possible to provide limited user access to 
patients, such that patients can complete the HAQ[8] at home prior to the consultation, in order to 
enhance the quality of the consultation. 
Data protection and safety 
All patient data in the METEOR database are anonymized, by storing all patient identifying data in an 
encrypted manner. Therefore, for none of the included countries – for example the Netherlands, 
Portugal, South Africa, Mexico and the USA – an informed consent is needed when adding new 
patients to the database. Identifying data can only be decrypted by the site that has created the 
data, so rheumatologists always have access to detailed data regarding their own patients. Since the 
METEOR database contains medical data, it is impossible to delete data. Instead, data may be 
invalidated in case of errors, such that new and correct data may be created. A yearly check is 
performed to ensure that data protection and safety are in accordance with data protection 
regulations of all included countries. 
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Upload and download facilities 
In recent years, an increasing number of hospitals have implemented Electronic Health Records 
(EHR) to record daily patient care. This means that using METEOR as a separate tool necessitates 
double data entry, thereby costing instead of saving time for the physician. In order to overcome the 
burden of double data entry, METEOR has developed upload and download facilities. With the 
download facility, data from the METEOR database can be uploaded in the local EHR system. The 
upload facility can be used to upload data from the local EHR system into the METEOR database, but 
it can also be used to link data from local databases to the METEOR database. The upload facility is 
currently being actively used in, among other countries, the Netherlands, Portugal[9] and India. 
Using the upload or download facilities enables users to benefit from the benchmark and research 
facilities, without the problem of double data entry or having to give up the local registries. 
 
The METEOR database contains a total of 200 data elements, grouped in a complex structure of 7 
tables. This structure ensures high speed data entry and data extraction for research purposes. It 
also allows for missing data, since tool users are not obliged to fill out all fields and it ensures 
internal consistency of the database. However, it also results in a very specific structure that is 
needed before data can be uploaded into the database. In general, between 150 and 200 data 
elements must be integrated in the METEOR database via the upload file. 
A standardised XML-file, together with a reference guide and additional documentation, have been 
developed, to convert data from local registries into the correct format for upload into the database. 
Data from the local registry must be extracted and stored in this XML-file before they can be 
uploaded. Since this process is rather complicated, a local IT-expert is needed, who can cooperate 
with a METEOR IT-expert in order to develop a standardised procedure for data extraction, 
conversion and upload. The completed XML-file may be uploaded in a testing environment for 
validation. During this validation procedure, the quality and internal consistency of the XML-file is 
tested, as well as the correct format of each item. Due to the complex database structure, the 
validation cannot be performed only on a field-by-field level, but the correct relationship between 
fields also must be tested in order to lead to a consistent database. For example, not only the 
individual joint scores are stored, but also the complete DAS.  
Whereas some items can be transferred directly from a local registry into METEOR, others require 
conversions. For example, medication data are often stored in different ways, which are not always 
consistent within one register. During the validation process, all possible errors and differences 
between the METEOR database and the register are identified, until all data can be uploaded in the 
correct format. When uncertainty still exists about the correctness of the data, these data are 
deleted, possibly leading to some missing values. According to experiences with already coupled 
registries, this is a relatively time-consuming process, requiring up to 5-10 subsequent attempts 
before all errors are eliminated. However, once this process has been completed, data from the 
XML-file can be relatively easily uploaded, according to the specified format. Then not only new data 
can be added to the database, but replacement of old data is also possible, in order to allow 
correction of erroneous data. 
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Research opportunities  
All METEOR users who are actively contributing data to the database, including those centres that 
add data through the upload facility, can perform research in the database. The leading principle is 
that each participating rheumatologist or centre is the owner of its own data. Therefore, each user 
can at any time perform research using her/his own data. Researchers also may submit research 
proposals with a request to perform research on part of or the complete METEOR database. These 
research proposals are assessed by a scientific committee regarding relevance, quality and ethical 
aspects. Once approved by the scientific committee, a representative rheumatologist of each site 
can decide if they allow their data to be used in that particular research project. 
 
Currently, the METEOR database contains data from >39,000 patients and >200,000 visits, added by 
78 sites using the METEOR tool and 50 sites using the upload facilities. These data stem from 32 
different countries, which are ever increasing. Since rheumatologists are not obliged to complete all 
fields and sometimes technical issues exist when coupling local registries to the database, not all 
data are complete. Therefore, continuous efforts are being undertaken to increase the quality of the 
data in the database. 
Nonetheless, the METEOR database offers unique research opportunities. Not only does its large size 
ensure a large statistical power to investigate an extensive variety of research questions.  
Furthermore, the strong international character of the database also offers a rare possibility to 
investigate cross-country differences. Although an increasing number of national databases exist, 
research questions regarding cross-country comparisons can be answered only by pooling 
information from these databases, which has already been performed in METEOR. Furthermore, 
since data are gathered in clinical practice, research questions regarding real life clinical practice can 
be answered. Some examples of research that has been performed in the METEOR database can be 
found in table 2. 
Conclusions and future perspectives 
The METEOR database was founded 10 years ago to stimulate treat-to-target, to improve patient 
care and to create an international RA research database. During these 10 years, many 
rheumatologists worldwide have started using the METEOR tool to follow-up their patients and to 
treat their patients more efficiently. Also, an increasing number of sites use the upload facilities to 
add data to the METEOR database, enabling them to benefit from the benchmark and research 
opportunities. This has led to the creation of a large international research database that offers a 
unique opportunity to study daily clinical practice and to perform research regarding cross-country 
differences. In the future, METEOR will continue to stimulate the worldwide use of the METEOR tool. 
Furthermore, in sites or countries in which EHRs are used in daily practice, efforts are being made to 
enable upload facilities; not only to increase the size of the database, but also its quality and the 
representativeness of the data for the country from which the data were obtained.  These efforts 
will increase the potential value of the database and the number of research questions that METEOR 
has the capacity to answer, helping us to better understand the disease and its treatment in 
different geographic and clinical settings, and to improve outcomes for our patients. 
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Table 1. Variables collected in METEOR (adapted from 
van den Berg et al.[10], with permission) 
Patient characteristics 
Age 
Gender 
Marital status 
Smoking habits 
Height 
Weight 
Disease characteristics 
Date of symptom onset 
Date of diagnosis 
Erosions (present/absent/unknown) 
Rheumatoid factor (present/absent/unknown) 
ACPA (present/absent/unknown) 
Tender joint count (53 or 28) 
Swollen joint count (44 or 28) 
Ritchie Articular Index 
Erythrocyte Sedimentation Rate levels 
C-Reactive Protein levels 
Comorbidities 
Physician reported outcomes 
Physician global disease activity 
Patient reported outcomes 
Patient global disease activity 
Visual Analogue Scale for pain 
Health Assessment Questionnaire 
RAPID3 
Treatment 
Drugs (type, dose, start and end date) 
Intra-articular injections 
Surgery 
ACPA = anti-citrullinated protein antibodies RAPID3 = 
Routine Assessment of Patient Index Data 
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Table 2. Examples of research projects performed in the METEOR database (adapted from van den Berg et 
al.[10], with permission). 
Topic Aim Conclusions 
Patient’s versus 
physician’s global 
disease activity[11;12] 
To compare the differences 
between patient and physician 
global disease activity and 
identify factors that might 
influence these differences. In 
addition, to assess whether these 
differences vary across 13 
countries. 
Differences between patients and physician 
global disease activity vary across countries. In 
general, agreement between patient and 
physician was moderate. In most countries 
patients scored on average higher than 
physicians. Patients based their judgment 
primarily on pain, whereas rheumatologists 
based it on swollen joint count and ESR level. 
DAS steered therapy in 
clinical practice[13] 
To evaluate treatment 
adjustments in response to DAS 
in RA patients in clinical practice 
in one centre in the Netherlands. 
The majority of patients assessed had already 
achieved low disease activity, reflecting 
appropriate treatment intensity. When DAS 
≥2.4, treatment was often not intensified due 
to high tender joint count or specific 
treatment combinations. This suggests that 
while aiming for low DAS, physicians have an 
individual approach, weighting whether all 
DAS elements are consistent with the total  
DAS and weather individual variables are likely 
to respond to DMARD adjustment or not. 
Obesity and disease 
activity[14] 
Is BMI associated with RA disease 
outcomes? 
In patients with established RA obesity was 
associated with higher DAS28 and reduced 
odds of achieving DAS28 remission. In early 
RA, obesity was not associated with adverse 
disease activity outcomes. 
Is there an effect of 
treat-to-target 
training?[15] 
To investigate if rheumatologists 
from several countries that 
report to agree with existing 
guidelines indeed follow them up 
in clinical practice. 
Reporting to be compliant with EULAR 
recommendations and T2T principles, even 
after dedicated education, does not mean that 
rheumatologists actually comply with it in 
clinical practice. 
TNF inhibitor use across 
countries[16] 
To investigate whether the 
relative distribution of TNFi 
prescriptions for RA varies among 
countries with different 
healthcare systems, during two 
time periods. 
The relative prescription of various TNFi 
differed significantly across several EU 
countries and the US. Infliximab was 
prescribed significantly more in EU countries 
compared to US sites in period 1 (2009-2010). 
In Italy and Portugal, etanercept was 
prescribed significantly more than other TNFi 
in period 2 (2011-2012). 
Comparison of RA 
disease activity indices 
in two populations[17] 
To assess disease activity states 
using DAS28, CDAI and SDAI and 
to compare their outcomes in 
two RA populations. 
CDAI and SDAI classified approximately the 
same number of patients in remission in 
Portugal and the Netherlands. DAS28 classified 
a higher percentage of Dutch patients as being 
in remission, due to a lower ESR. 
Quality indicators in RA 
in clinical practice[18] 
To test the feasibility of 
collecting, storing, retrieving and 
analyzing necessary information 
to fulfil a preliminary set of 
quality indicators  that have been 
proposed by an international task 
force. 
Most of the quality indicators that were 
proposed by the task force were feasible in 
clinical practice in most parts of the world. 
ESR = erythrocyte sedimentation rate, DAS = disease activity score, DMARD = disease modifying anti-rheumatic 
drug, EULAR = European League Against Rheumatism, T2T = treat to target, RA = rheumatoid arthritis, TNFi = 
TNF inhibitors, EU = European, US = United States, CDAI = clinical disease activity index, SDAI = simplified 
disease activity index 
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